# MORPHEUS-UC (NCT03869190)

> Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03869190
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: Hoffmann-La Roche
- Conditions: Urothelial Carcinoma; Bladder Cancer
- Interventions: Atezolizumab; Enfortumab Vedotin; Niraparib; Magrolimab (Hu5F9-G4); Tiragolumab; Sacituzumab Govitecan; Tocilizumab; Cisplatin; Gemcitabine
- Enrollment: 272
- Primary outcome: Stage 1 mUC Cohorts: Objective Response Rate (ORR)
- Primary outcome: MIBC Cohorts: Pathological Complete Response (pCR)

## Indexed commentary on MORPHEUS-UC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- Podcasts: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=morpheus-uc-nct03869190

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03869190", "email": "<work email>"}; the inbox owner confirms by the emailed link.